Acute Pancreatitis After Initiating Dulaglutide in a Patient Previously Treated With a DPP-4 Inhibitor: Case Report From Palestine.

Nasser A, Ladadweh H, Madia R, Dalashi A, Wahdan A, Alawi A

Case reports in gastrointestinal medicine28 Nov 2025

PMID41355891PMCIDPMC12680473DOI10.1155/crgm/9918202PepBankPUB-41355891

Summary

BackgroundDulaglutide, a glucagon-like peptide-1 (GLP-1) agonist, is utilized for the management of type 2 diabetes and obesity, typically administered subcutaneously at a dosage of 0.75 mg/0.5 mL once weekly, with adjustments made as needed. While typically well tolerated, it may induce infrequent yet severe adverse effects, including acute pancreatitis.Case presentationIn this case report, we present the first documented case of GLP-1-induced pancreatitis in Palestine. A 62-year-old female Palestinian patient with a history of type 2 diabetes complicated with nephropathy, hypertension, dyslipidemia, and cardiac catheterization three years prior without stenting. The patient developed acute pancreatitis following the initiation of 1.5 mg of a GLP-1 receptor agonist after 4 months of therapy. The patient experienced upper abdominal pain radiating to the back, nausea, and alternating diarrhea and constipation for 5 days. Laboratory investigations revealed elevated serum amylase and lipase levels, and imaging studies confirmed signs of acute pancreatitis. After the GLP-1 agonist was discontinued, the patient's symptoms improved, and she fully recovered.ConclusionGLP-1 receptor agonists are advantageous for the management of diabetes and obesity but may precipitate acute pancreatitis in predisposed individuals. Clinicians should be aware of this potential risk and promptly investigate any patient who presents with signs of acute abdominal pain during GLP-1 therapy.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanCase report or seriesSafety outcome
A woman with T2D developed acute pancreatitis after dulaglutide initiation.
In plain wordsA woman with T2D developed acute pancreatitis after dulaglutide initiation.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableAcute pancreatitis
Study
n = 1
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1.5 mg · 4 monthsAs given in this study (human).
Source sentences
Summary
The patient developed acute pancreatitis following the initiation of 1.5 mg of a GLP-1 receptor agonist after 4 months of therapy.
2 context sentences(design, population, supporting numbers)
Title · context
Acute Pancreatitis After Initiating Dulaglutide in a Patient Previously Treated With a DPP-4 Inhibitor: Case Report From Palestine.
Summary · context
A 62-year-old female Palestinian patient with a history of type 2 diabetes complicated with nephropathy, hypertension, dyslipidemia, and cardiac catheterization three years prior without stenting.
Show in the study text Report a problemFND-4135589101
02HumanCase report or seriesSafety outcome
A woman with T2D experienced upper abdominal pain radiating to the back during pancreatitis after dulaglutide initiation.
In plain wordsA woman with T2D experienced upper abdominal pain that spread to her back after dulaglutide initiation.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableUpper abdominal pain
Study
n = 1
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1.5 mg · 4 monthsAs given in this study (human).
Source sentences
Summary
The patient experienced upper abdominal pain radiating to the back, nausea, and alternating diarrhea and constipation for 5 days.
2 context sentences(design, population, supporting numbers)
Summary · context
A 62-year-old female Palestinian patient with a history of type 2 diabetes complicated with nephropathy, hypertension, dyslipidemia, and cardiac catheterization three years prior without stenting.
Summary · context
The patient developed acute pancreatitis following the initiation of 1.5 mg of a GLP-1 receptor agonist after 4 months of therapy.
Show in the study text Report a problemFND-4135589102
03HumanCase report or seriesSafety outcome
A woman with T2D experienced nausea during pancreatitis after dulaglutide initiation.
In plain wordsA woman with T2D experienced nausea during pancreatitis after dulaglutide initiation.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableNausea
Study
n = 1
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1.5 mg · 4 monthsAs given in this study (human).
Source sentences
Summary
The patient experienced upper abdominal pain radiating to the back, nausea, and alternating diarrhea and constipation for 5 days.
2 context sentences(design, population, supporting numbers)
Summary · context
A 62-year-old female Palestinian patient with a history of type 2 diabetes complicated with nephropathy, hypertension, dyslipidemia, and cardiac catheterization three years prior without stenting.
Summary · context
The patient developed acute pancreatitis following the initiation of 1.5 mg of a GLP-1 receptor agonist after 4 months of therapy.
Show in the study text Report a problemFND-4135589103
04HumanCase report or seriesSafety outcome
A woman with T2D experienced alternating diarrhea and constipation during pancreatitis after dulaglutide initiation.
In plain wordsA woman with T2D had alternating diarrhea and constipation after dulaglutide initiation.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableAlternating diarrhea and constipation
Study
n = 1
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1.5 mg · 4 monthsAs given in this study (human).
Source sentences
Summary
The patient experienced upper abdominal pain radiating to the back, nausea, and alternating diarrhea and constipation for 5 days.
2 context sentences(design, population, supporting numbers)
Summary · context
A 62-year-old female Palestinian patient with a history of type 2 diabetes complicated with nephropathy, hypertension, dyslipidemia, and cardiac catheterization three years prior without stenting.
Summary · context
The patient developed acute pancreatitis following the initiation of 1.5 mg of a GLP-1 receptor agonist after 4 months of therapy.
Show in the study text Report a problemFND-4135589104
05HumanCase report or seriesSafety outcome
A woman with T2D had elevated serum amylase during pancreatitis after dulaglutide initiation.
In plain wordsA woman with T2D had elevated serum amylase during pancreatitis after dulaglutide initiation.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseSerum amylase
Study
n = 1
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1.5 mg · 4 monthsAs given in this study (human).
Source sentences
Summary
Laboratory investigations revealed elevated serum amylase and lipase levels, and imaging studies confirmed signs of acute pancreatitis.
2 context sentences(design, population, supporting numbers)
Summary · context
A 62-year-old female Palestinian patient with a history of type 2 diabetes complicated with nephropathy, hypertension, dyslipidemia, and cardiac catheterization three years prior without stenting.
Summary · context
The patient developed acute pancreatitis following the initiation of 1.5 mg of a GLP-1 receptor agonist after 4 months of therapy.
Show in the study text Report a problemFND-4135589106
06HumanCase report or seriesSafety outcome
A woman with T2D had elevated serum lipase during pancreatitis after dulaglutide initiation.
In plain wordsA woman with T2D had elevated serum lipase during pancreatitis after dulaglutide initiation.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseSerum lipase
Study
n = 1
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1.5 mg · 4 monthsAs given in this study (human).
Source sentences
Summary
Laboratory investigations revealed elevated serum amylase and lipase levels, and imaging studies confirmed signs of acute pancreatitis.
2 context sentences(design, population, supporting numbers)
Summary · context
A 62-year-old female Palestinian patient with a history of type 2 diabetes complicated with nephropathy, hypertension, dyslipidemia, and cardiac catheterization three years prior without stenting.
Summary · context
The patient developed acute pancreatitis following the initiation of 1.5 mg of a GLP-1 receptor agonist after 4 months of therapy.
Show in the study text Report a problemFND-4135589107
07HumanCase report or seriesSafety outcome
A woman with T2D improved and fully recovered after dulaglutide withdrawal following pancreatitis.
In plain wordsA woman with T2D improved compared with before dulaglutide withdrawal and fully recovered after pancreatitis.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseRecovery after withdrawal
Study
n = 1
Comparator
Before withdrawal
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
After the GLP-1 agonist was discontinued, the patient's symptoms improved, and she fully recovered.
2 context sentences(design, population, supporting numbers)
Summary · context
A 62-year-old female Palestinian patient with a history of type 2 diabetes complicated with nephropathy, hypertension, dyslipidemia, and cardiac catheterization three years prior without stenting.
Summary · context
The patient developed acute pancreatitis following the initiation of 1.5 mg of a GLP-1 receptor agonist after 4 months of therapy.
Show in the study text Report a problemFND-4135589108

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.